Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2009
11/03/2009US7611721 Adjuvant combination formulations
11/03/2009US7611708 Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
11/03/2009CA2457982C Use of nefiracetam for treating neurodegeneration
11/03/2009CA2449729C Prodrugs of gaba analogs, compositions and uses thereof
11/03/2009CA2442423C Therapeutic drug for psychoneurotic disorders
11/03/2009CA2421990C .beta.-thioamino acids
11/03/2009CA2420579C Process for the racemisation of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2,3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine
11/03/2009CA2418961C Anti-il-12 antibodies, compositions, methods and uses
11/03/2009CA2410037C 3-phenyl-imidazo-pyrimidine derivatives as ligands for gaba receptors
11/03/2009CA2409926C Praziquantel compounds for treating diseases due to sarcocystis, neospora, toxoplasma and isospora
11/03/2009CA2383327C Thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives useful as d4 antagonists
11/03/2009CA2383220C Controlled release pellet formulation
11/03/2009CA2372668C Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts
11/03/2009CA2353133C Treatment of disorders secondary to organic impairments
11/03/2009CA2316356C Benzoxazine compounds for enhancing synaptic response
11/03/2009CA2191064C Pantropic neurotrophic factors
11/03/2009CA2187626C Aav-mediated delivery of dna to cells of the nervous system
10/2009
10/30/2009CA2638573A1 Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions
10/29/2009WO2009132253A1 Use of epothelone d in treating tau-associated diseases including alzheimer's disease
10/29/2009WO2009132149A2 Treatment of conditions related to cecal ligation shock
10/29/2009WO2009131975A1 Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
10/29/2009WO2009131974A1 Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
10/29/2009WO2009131940A1 Limk2 inhibitors, compositions comprising them, and methods of their use
10/29/2009WO2009131926A1 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
10/29/2009WO2009131815A1 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands
10/29/2009WO2009131191A1 Metastin derivative and use thereof
10/29/2009WO2009131171A1 Novel five-membered ring compound
10/29/2009WO2009131170A1 Five-membered ring compound
10/29/2009WO2009131096A1 Compound having npy y5 receptor antagonist activity
10/29/2009WO2009130600A2 Therapeutic use of at least one botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy
10/29/2009WO2009130434A1 INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE
10/29/2009WO2009130422A2 N-acylthiourea and n-acylurea inhibitors of the hedgehog protein signalling pathway
10/29/2009WO2009130317A1 1- (7-(hexahydropyrrolo [3, 4-c] pyrrol-2 (1h) -yl) quin0lin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (gsk-3)
10/29/2009WO2009130272A1 Nalmefene prodrugs
10/29/2009WO2009130270A1 Nalmefene di-ester prodrugs
10/29/2009WO2009130264A1 PROCESS FOR PREPARING A CRYSTALLINE FORM COMPOUND OF 3-BENZYL-2-METHYL-2,3,3a,4,5,6,7,7a-OCTAHYDROBENZO[d]ISOXAZOL-4-ONE
10/29/2009WO2009130263A1 PROCESS FOR PREPARING A CRYSTALLINE FORM COMPOUND OF 3-BENZYL-2-METHYL-2,3,3a,4,5,6,7,7a-OCTAHYDROBENZO[d]ISOXAZOL-4-ONE
10/29/2009WO2009130253A1 Chromenone derivatives useful for the treatment of neurodegenerative diseases
10/29/2009WO2009130240A1 Isoquinolinone derivatives as nk3 antagonists
10/29/2009WO2009130234A1 (5r)-1,5-diaryl-4,5-dihydro-1h-pyrazole-3-carboxamidine derivatives having cb1-antagonistic activity
10/29/2009WO2009130232A1 Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors
10/29/2009WO2009130231A1 Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists
10/29/2009WO2009129833A1 Compartment-specific plant extract combination of ginkgo biloba extract and ginseng extract having a tandem effect
10/29/2009WO2009129726A1 Nitrone compounds, process of preparation thereof, and use thereof in medicament manufacture
10/29/2009WO2009129696A1 A kind of receptor signaling transoluction positive modulators, preparation methods and uses thereof
10/29/2009WO2009129578A1 Methods for radiolabelling synthetic polymers
10/29/2009WO2009109911A8 Methods of treating chronic pain
10/29/2009WO2009109493A3 2-aminoquinoline derivatives as 5-ht ( 5a) receptor antagonists
10/29/2009WO2009106980A3 Indazole derivatives
10/29/2009WO2009106831A3 Pharmaceutical composition comprising naltrexone
10/29/2009WO2009105504A3 Functionally selective alpha2c adrenoreceptor agonists
10/29/2009WO2009103932A8 Use of a cardiac glycoside and/or a diuretic for the treatment of neuropathic pain
10/29/2009WO2009097567A4 Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
10/29/2009WO2009093208A3 Substituted 2-amino-3-sulfonyl-pyrazolo[1,5-a] pyrimidines/antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof
10/29/2009WO2009093206A3 3-sulfonyl-pyrazolo[1,5-a] pyrimidines / antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof
10/29/2009WO2009087568A3 Compositions comprising antioxidant and mitoprotective flavonoids with neuroprotective properties
10/29/2009WO2009075607A3 Pharmaceutical preparation comprising stephaglabrin sulfate for treating demyelinating diseases of the nervous system and for promoting restoration of the myelin sheath of nerve fibers
10/29/2009WO2009046856A3 Use of serorphin as a therapeutic agent
10/29/2009WO2009046824A3 Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis
10/29/2009WO2009043505A3 Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer
10/29/2009WO2009043504A3 Use of apelin-36 and optionally beta-melanotropin as therapeutic agents, eg for treating aids or alzheimer
10/29/2009WO2009040089A3 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents
10/29/2009WO2009039996A3 Use of bradykinin alone or in combination with melanotan ii as a therapeutic agent
10/29/2009WO2009039977A3 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hbv infection
10/29/2009WO2009039461A3 N-substituted piperidine derivatives as serotonin receptor agents
10/29/2009WO2009033781A3 Use of k237 as therapeutic agent
10/29/2009WO2009033751A3 Use of leu-enkephalin as a therapeutic agent
10/29/2009WO2009033718A3 Use of anti -inflammatory peptide 1 as a therapeutic agent
10/29/2009WO2008122119A8 Perfluoroketone compounds and uses thereof
10/29/2009US20090270513 3,5-dihydroxy-2,4-cyclohexadienones and their derivatives, dietary compositions and fortified food containing them and their uses
10/29/2009US20090270508 GluR2 receptor modulators
10/29/2009US20090270504 Treatment of Huntington's Disease With EPA
10/29/2009US20090270493 prodrugs of gabapentin and pregabalin, such as 2-[1-[[[(2R)-6-oxooxan-2-yl]oxycarbonylamino]methyl]cyclohexyl]aceticacid, used for for treating epilepsy, depression, anxiety, psychosis, brain disorders, neurodegenerative diseases, pain, inflammatory disease, gastrointestinal disorders or drug abuse
10/29/2009US20090270478 Ion channel modulating activity ii
10/29/2009US20090270458 Method of treating of demyelinating diseases or conditions
10/29/2009US20090270453 Anti-manic effective doses of sertindole
10/29/2009US20090270451 Piperdine Glycine Transporter Inhibitors
10/29/2009US20090270442 Polymorphs of hydrochloride salt of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
10/29/2009US20090270439 Prophylactic/therapeutic agent for alzheimer's disease
10/29/2009US20090270432 7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]-2-(1-PROPYNYL)-7H-PYRAZOLO-[4,3-e]-[1,2,4]-TRIAZOLO-[1,5-c]-PYRIMIDIN-5-AMINE
10/29/2009US20090270427 Purine derivatives
10/29/2009US20090270421 Inhibitors of fatty acid amide hydrolase
10/29/2009US20090270413 Di-t-butylphenyl piperazines as calcium channel blockers
10/29/2009US20090270412 Pyrido[3,4-b]indoles and methods of use
10/29/2009US20090270408 Amide derivatives as positive allosteric modulators and methods of use thereof
10/29/2009US20090270405 nicotinic receptor ligands such as N-(benzo[d]thiazol-2-yl)-4H-1'-azaspiro[oxazole-5,3'-bicyclo[2.2.2]octan]-2-amine, used for the treatment of nervous system, psychological and neurodegenerative disorders; treatment of schizophrenia or Alzheimer's Disease
10/29/2009US20090270403 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use
10/29/2009US20090270402 Novel triazolopyridazines
10/29/2009US20090270401 Use of a dihydroimidazopyrazoine derivative for treating or preventing pain
10/29/2009US20090270376 Heterocyclic janus kinase 3 inhibitors
10/29/2009US20090270373 Treatment of down syndrom with benzodiazepine receptor antagonists
10/29/2009US20090270372 Melanocortin receptor MC4 modulators; obesity, sexual disorders, anxiolytic agents, analgesics, antidepressants; 6-(aminomethyl)-2-aminobenzimidazole derivatives
10/29/2009US20090270371 Quinoline derivatives useful in the treatment of mglur5 receptor-mediated disorders
10/29/2009US20090270369 Bicycloamine derivatives
10/29/2009US20090270367 Substituted hydroxyethylamine aspartyl protease inhibitors
10/29/2009US20090270365 such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics
10/29/2009US20090270364 Substituted pyrimidine derivatives
10/29/2009US20090270362 Bicyclic mglur5 positive allosteric modulators and methods of making and using same
10/29/2009US20090270338 Diaryl-cyclylalkyl derivatives as calcium channel blockers
10/29/2009US20090270334 Neuronal differentiation inhibitor peptide and use thereof
1 ... 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 ... 1833